

Autoimmune haemolytic anaemia associated with COVID-19 infection

Among patients with SARS-CoV-2 infection (also known as COVID-19), pneumonia, respiratory failure and acute respiratory distress syndrome are frequently encountered complications.¹ Although the pathophysiology underlying severe COVID-19 remains poorly understood, accumulating evidence argues for hyperinflammatory syndrome causing fulminant and fatal cytokines release associated with disease severity and poor outcome.² However, the spectrum of complications is broader and includes among others various auto-immune disorders such as autoimmune thrombocytopenia, Guillain-Barré and antiphospholipid syndrome.³⁻⁵ In this report we describe seven patients from six French and Belgian Hospitals who developed a first episode of autoimmune haemolytic anaemia (AIHA) during a COVID-19 infection.

Patient characteristics are detailed in Table I. Briefly, median age was 62 years (range, 61–89 years), and all patients presented with risk factors for developing a severe form of COVID-19 such as hypertension, diabetes and chronic renal failure. All patients had both a positive oropharyngeal swab for SARS-CoV-2 and typical images of COVID-19 infection on chest computed tomography scans (25–75% extension). Three patients were admitted in an intensive care unit but only one required invasive ventilation. Treatment for COVID-19 infection differed according to the standards of each centre. Thus, three patients received hydroxychloroquine, in association with azithromycin for two of them, and one patient received lopinavir and ritonavir.

The median time between the first COVID-19 symptoms and AIHA onset was nine days (range 4–13 days), and haemoglobin level decreased by more than 30 g/l in all cases. Median haemoglobin level at the time of AIHA diagnosis was 70 g/l (range 3.8–10.8), and all patients presented with marked haemolysis signs. Direct antiglobulin test (DAT) was positive in all cases either for IgG ($n = 2$), for C3d ($n = 2$), or for both IgG and C3d ($n = 3$). Anti-erythrocyte antibodies were warm antibodies in four cases (two of IgG specificity and two IgG + C3d) and cold agglutinins in three cases (two of C3d specificity and one IgG + C3d). At the time of AIHA onset, all patients had elevated markers of inflammation (i.e. fibrinogen, D-dimers and C-reactive protein).

Interestingly, among the patients with warm antibodies, two patients were known for stable untreated Binet stage A chronic lymphocytic leukaemia (CLL); an IgG kappa monoclonal gammopathy of undetermined significance was

demonstrated in a third one. In 2/3 patients with cold agglutinin, systematic lymphocyte immunophenotyping demonstrated the presence of a monotypic B lymphoid population with a phenotype compatible with marginal zone lymphoma (MZL). The third one was diagnosed with prostate cancer.

AIHA management included corticosteroids for five patients, and red blood cells infusions for two. Even if the follow-up is still short, three patients receiving corticosteroids were evaluable for response of AIHA. Two patients reached partial response defined by haemoglobin level >100 g/l along with an increase of 20 g/l at least seven days after an infusion with red blood cells.

Corticosteroid failure lead to rituximab injection in the third case (patient #6), and one responding patient is scheduled to receive rituximab because of a MZL clone (patient #3).

At the time of last follow-up, all patients were alive and had at least partly recovered from COVID-19.

To conclude, we report seven cases of warm and cold AIHA associated with COVID-19 disease, all of them occurring after the beginning of the symptoms of the infection and within a timeframe compatible with that of the cytokine storm. Four out of the seven patients had indolent B lymphoid malignancy either already known or discovered because of the haemolytic episode. AIHA is a classical complication of both CLL and MZL,^{6,7} and viral infections are known to trigger autoimmune cytopenias.⁸ Whether the presence of an underlying malignant B lymphoid clone facilitated the onset of AIHA is unknown. Nonetheless, these observations argue for systematically investigating for the presence of a lymphoid clone in patients presenting with COVID-19 infections and autoimmune cytopenias.

Acknowledgements

The authors thank the French Innovative Leukemia Organization (FILO) group for initiating the study.

Author contributions

GL, AQ and FC designed the research study, analyzed the data and wrote the paper. MB, JS, CJ, DR, FM, AM, TB, GD and AD contributed to conception, patient enrollment and data collection.

Table I. Characteristics of seven patients with autoimmune haemolytic anaemia after the onset of COVID-19.

Patient	Age	Gender	Comorbidity	CT-scan*	Oropharyngeal swab (tested by PCR)	Hae-moglobin (g/l)	Reticulocyte count ($10^9/l$)	Lymphocyte count ($10^9/l$)	Lactate dehydrogenase (U/l)	Hap-toglobin (g/l)	DAT specificity	Optimum temperature	Day between COVID-19 symptoms and AIHA pathology treatment	Response
#1	61	M	Hypertension, chronic renal failure	Moderate	Positive	60	477	250	1000	<0.1	IgG + C3d	warm	13	CLL Steroids Ongoing
#2	89	F	Hypertension, chronic renal failure, atrial fibrillation	Mild	Positive	84	103	1.7	598	<0.1	IgG + C3d	warm	7	MGUS Steroids Ongoing
#3	62	F	Hypertension, cirrhosis	Severe	Positive	108	101	1.3	357	<0.1	C3d	cold	4	MZL† 1. Steroids 2. Rituximab Planned
#4	69	F	Obesity	Moderate	Positive	38	215	5.9	2610	<0.1	IgG + C3d	cold	10	MZL Steroids PR
#5	61	M	Hypertension, chronic renal failure, diabetes, hypercholesterolaemia	Mild	Positive	72	145	3	807	0.8	C3d	cold	11	Prostate cancer RBC infusion Ongoing
#6	61	M	Diabetes	Severe	Positive	70	155	1.2	1800	<0.1	IgG	warm	9	None 1. Steroids 2. Rituximab‡ Failure Ongoing
#7	75	M	Diabetes, hypercholesterolaemia, cardiopathy, obesity, chronic obstructive bronchopneumopathy	Moderate	Positive	71	98	108	2000	<0.1	IgG	warm	6	CLL RBC infusion Ongoing

CT, computed tomography; PCR, polymerase chain reaction; DAT, direct antiglobulin test; AIHA, autoimmune haemolytic anaemia; CLL, chronic lymphocytic leukaemia; MGUS, monoclonal gammopathy of undetermined significance; MZL, marginal zone lymphoma; RBC, red blood cells; PR, partial response.

*Degree of involvement of the lung was classified as none (0%), minimal (1–25%), mild (26–50%), moderate (51–75%), or severe (76–100%).

†MZL B cell clone was detected in the bone marrow.

‡Patient 6 received rituximab injection because of corticosteroid failure.

Gregory Lazarian^{1,†} 
 Anne Quinquenel^{2,†} 
 Mathieu Bellal³
 Justine Siavellis¹
 Caroline Jacquy⁴
 Daniel Re⁵
 Fatiha Merabet⁶
 Arsene Mekinian⁷
 Thorsten Braun¹
 Gandhi Damaj³
 Alain Delmer² 
 Florence Cymbalista¹

¹Hôpital Avicenne, Assistance Publique – Hôpitaux de Paris, Université Paris 13, Bobigny, ²CHU de Reims, Hôpital Robert-Debré, Université Reims Champagne-Ardenne, Reims, ³Centre Hospitalier Régional Universitaire, Caen, France, ⁴CHU Ambroise Paré, Mons, Belgique, ⁵Hôpital Général d'Antibes, Antibes, ⁶Hôpital de Versailles, Université Versailles – Saint Quentin, Le Chesnay and ⁷Hôpital Saint-Antoine, Assistance Publique – Hôpitaux de Paris, Paris, France.
 E-mail: florence.cymbalista@aphp.fr

[†]These authors contributed equally.

Keywords: COVID-19, autoimmune hemolytic anemia, B-cell lymphoproliferative disorder

First published online 27 May 2020
 doi: 10.1111/bjh.16794

References

- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;**395**:1054–62.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;**395**:1033–4.
- Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré Syndrome associated with SARS-CoV-2. *N Engl J Med*. 2020;NEJMc2009191. [Epub ahead of print].
- Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med*. 2020;**382**:e38.
- Zulfiqar, A-A, Lorenzo-Villalba, N, Hassler, P & Andrès, E. Immune thrombocytopenic Purpura in a patient with Covid-19. *New Engl J Med*. 2020;**382** (18):e43.
- Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khaloufi M, et al. Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. *Am J Hematol*. 2015;**90**:E5–8.
- Sallah S, Sigounas G, Vos P, Wan JY, Nguyen NP. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. *Ann Oncol*. 2000;**11**:1571–7.
- Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. *Am J Hematol*. 2002;**69**:258–71.

Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia

In rare cases, autoimmune haemolytic anaemia (AIHA) can complicate infections. We wish to report a case of simultaneous presentation of COVID-19 disease and warm AIHA.

A 46-year-old female with a medical history of congenital thrombocytopenia not on therapy presented with dyspnoea and cough to the Emergency Department. She was found to have pneumonia after chest computed tomography revealed a dense left upper lobe consolidation with minimal surrounding ground glass opacities and no evidence of pulmonary embolism (Fig 1). She had normal vital signs and pulse oximetry on ambient air. She was initiated on azithromycin 500 mg on day 1 then 250 mg daily and discharged home.

Her symptoms worsened over three days with progressive cough and dyspnoea. Her vital signs were a temperature of 40°C, pulse 130 bpm, respiratory rate 20 breaths per min, blood pressure 123/83 mm Hg and SpO₂ 99% on ambient

air. Her exam was only notable for diminished left-sided breath sounds. Laboratory studies gave haemoglobin 9.7 g/l, white blood cells $9.85 \times 10^3/\mu\text{l}$ with lymphopenia ($0.68 \times 10^3/\mu\text{l}$), and platelets $43 \times 10^3/\mu\text{l}$. Lactate dehydrogenase (LDH) was 296 U/l. She was admitted to the hospital.

Her Coombs test was positive, with direct antibody testing positive for IgG and C3. A test for antinuclear antibody (ANA) was negative. On hospital day 3, she was found to be positive for SARS-CoV-2 and started on hydroxychloroquine 400 mg bid on day 1, then 200 mg bid for four days because of its theoretical antiviral activity. Influenza, respiratory syncytial virus (RSV), viral respiratory polymerase chain reaction (PCR) panel, blood cultures and urine antigens for *Streptococcus pneumoniae* and legionella were negative.

Given her active COVID-19 disease she was started initially on intravenous immunoglobulin (IVIG) at 1 g/kg/day rather than prednisone. Despite this, she required transfusion